IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.078
EU - Europa 1.560
AS - Asia 828
SA - Sud America 35
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.062
IE - Irlanda 584
SG - Singapore 448
SE - Svezia 441
CN - Cina 302
IT - Italia 185
AT - Austria 107
DE - Germania 61
FI - Finlandia 55
BR - Brasile 32
FR - Francia 29
BE - Belgio 22
GB - Regno Unito 19
ID - Indonesia 19
CA - Canada 15
CZ - Repubblica Ceca 14
RU - Federazione Russa 12
IN - India 11
NL - Olanda 11
TR - Turchia 11
CI - Costa d'Avorio 10
IR - Iran 8
LT - Lituania 8
HK - Hong Kong 7
VN - Vietnam 6
JP - Giappone 5
BD - Bangladesh 3
DZ - Algeria 2
KR - Corea 2
KZ - Kazakistan 2
UA - Ucraina 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
BS - Bahamas 1
CH - Svizzera 1
CO - Colombia 1
CY - Cipro 1
EC - Ecuador 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
PL - Polonia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 4.516
Salva come PNG Salva come JPEG
Città #
Dublin 578
Chandler 462
Singapore 336
Santa Clara 306
Boardman 169
Ashburn 165
Princeton 113
Vienna 106
Shanghai 95
Ann Arbor 79
Beijing 65
Helsinki 54
New York 39
Bremen 28
Wilmington 26
Des Moines 24
Brussels 21
Milan 20
Parma 20
Jakarta 19
Chicago 15
Dearborn 12
Los Angeles 12
London 11
Abidjan 10
Bologna 10
Marseille 10
Munich 10
Rome 10
Seattle 10
Brno 9
Nanjing 9
Toronto 8
Verona 8
Borås 7
Fremont 7
Rio Saliceto 7
Dong Ket 6
Fairfield 6
Frankfurt am Main 6
Hong Kong 6
Houston 6
Jinan 6
Modena 6
San Mateo 6
Izmir 5
Menlo Park 5
Pune 5
Tianjin 5
Woodbridge 5
Ardea 4
Dallas 4
Hefei 4
Kish 4
Kocaeli 4
Kunming 4
Nuremberg 4
Olomouc 4
Redwood City 4
St Petersburg 4
São Paulo 4
Washington 4
Wayne 4
West Jordan 4
Changsha 3
Deiva Marina 3
Guangzhou 3
Hangzhou 3
Hebei 3
Huizen 3
Leipzig 3
Macomer 3
Moscow 3
Nanchang 3
Padova 3
Pavia 3
Phoenix 3
Reggio Emilia 3
Rockville 3
Sala Baganza 3
Shenyang 3
Stockholm 3
Taiyuan 3
Wuhan 3
Yangzhou 3
Zhengzhou 3
Alcamo 2
Almaty 2
Atlanta 2
Bagnolo in Piano 2
Bend 2
Bisceglie 2
Boston 2
Brasília 2
Buffalo 2
Calvi Risorta 2
Chengdu 2
Chongqing 2
Daejeon 2
Delhi 2
Totale 3.113
Salva come PNG Salva come JPEG
Nome #
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 107
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 106
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 104
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 84
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 79
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 74
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 73
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 73
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 70
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 68
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 65
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 63
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 63
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 62
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 61
The effect of COVID-19 emergency in the management of melanoma in Italy 61
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 61
Review on radiological evolution of COVID-19 pneumonia using computed tomography 61
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 61
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 59
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 59
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 59
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 59
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 56
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 54
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 54
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 53
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 52
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 52
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 52
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 50
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 50
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 48
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 48
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 48
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 47
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 46
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 46
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 46
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 45
Cabozantinib in RCC: only a METEOR or a rising star? 44
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 44
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 43
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 43
Avelumab Maintenance for Urothelial Carcinoma 42
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 41
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 41
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 40
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 40
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 40
Renal cell carcinoma and viral infections: A dangerous relationship? 39
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 37
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 37
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 37
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 37
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 37
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 37
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 37
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 36
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 36
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 36
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 35
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 34
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 34
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 32
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 32
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 31
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 31
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 31
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 31
Pazopanib in renal cell carcinoma dialysis patients: A mini-review and a case report 30
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 30
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 29
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 29
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 29
Reassessing Human Adipose Tissue 29
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer 27
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 27
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 27
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 26
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 26
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 25
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials 25
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 23
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 23
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma 22
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 22
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 22
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 21
Combination therapy in kidney cancer: The next revolution? 21
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis 21
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 21
Systemic adjuvant therapies in renal cell carcinoma 20
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 20
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 20
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 20
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: A pooled analysis of 926 patients 19
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 2 - Prostate and bladder cancer 19
Upfront chemohormonal therapy for prostate cancer: Neutropenia and G-CSF use 19
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 19
Totale 4.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.460
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.460
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020107 0 0 0 0 0 0 13 16 10 45 21 2
2020/2021150 2 1 4 22 7 23 9 13 22 19 10 18
2021/2022541 11 14 13 24 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/20251.095 38 154 195 111 226 351 20 0 0 0 0 0
Totale 4.712